Antiestrogen or estrogen as anticancer drug

Sex Hormones: Development, Regulation and Disorders

Volumn , Issue , 2011, Pages 75-94

  Suba, Zsuzsanna ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892116971     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (112)

1. Beatson TG: On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new treatment with illustrative cases. Lancet 2: 104-107, 1896.
2. Berrino F, Muti P, Micheli A, Bolelli G, Krogh V, Sciajno R et al Serum sex hormon levels after menopause and subsequent breast cancer. J. Natl. Cancer Inst. 88: 291-296, 1996.
3. Grady D: Postmenopausal hormones-therapy for symptoms only. New Engl. J. Med. 348: 1-3, 2003.
4. International Agency for Research on Cancer: Monographs on the evaluation of carcinogenic risks to humans: hormonal contraception an postmenopausal hormone therapy. Vol 72. IARC, Lyon, 1999.
5. Russo J, Ao X, Grill C, Russo IH: Pattern of distribution of cells positive for estrogen receptor α and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res. Treat 53: 217-227, 1999.
6. La Vecchia C, Brinton LA, McTiernan A: Menopause, hormone replacement therapy and cancer. Maturitas 39: 97-115, 2001.
7. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C: Hormone replacement therapy and cancer risk: a systematic analysis from a network of casecontrol studies. Int. J. Cancer 105: 408-412, 2003.
8. Gallus S, Bosetti C, Franceschi S, Levi F, Simonato L, Negri E, La Vecchia C: Oesophageal cancer in women: tobacco, alcohol, nutritional and hormonal factors. Br. J. Cancer 85: 341-345, 2001.
9. Olsson H, Bladströ m AM, Ingvar C: Are smoking-associated cancers prevented or postponed in women using hormone replacement therapy? Obstet. Gynecol. 102: 565-570, 2003.
10. Parazzini F, La Vecchia C, Negri E, Franceschi S, Bolis G: Case-control study of estrogen replacement therapy and risk of cervical cancer. Br. Med. J. 315: 85-88, 1997.
11. Rodriguez C, Feigelson HS, Deka A, Patel AV, Jacobs EJ, Thun MJ, Calle EE: Postmenopausal hormone therapy and lung cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol. Biomarkers Prev. 17: 655-660, 2008.
12. Ascenzi P, Bocedi A, Marino M: Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Mol. Aspects Med. 27: 299-402, 2006 .
13. Suba Zs: Common soil of smoking-associated and hormone-related cancers: estrogen deficiency. Oncol. Rev. 4: 73-87, 2010.
14. Suba Zs: Re-evaluation of the epidemiological associations of female sexual steroids and cancer risk, Chapter VI. pp. 108-125 In: Estrogen versus Cancer, Nova Science Publishers, New York, 2009.
15. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullian MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Women's Health Intitative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterctomy: the Women's Health Intitative randomized controlled trial. JAMA 291: 1701-1712, 2004.
16. Anderos GL, Judd HL, Kaunitz AM Women's Health Initiative Investigator Effects of estrogen plus progestin on gynaecologic cancers and associated diagnostic procedures: The Women's Health Initative randomised trial. JAMA 290: 1739-1748, 2003.
17. Schapiro S: False alarm: postmenopausal hormone therapy and ovarian cancer. Climacteric 10: 466-470, 2007.
18. Britt K, Ashworth A, Smalley M: Pregnancy and the risk of breast cancer. Endocrine-Related Cancer 14: 907-933, 2007.
19. Rajkumar L, Guzman RC, Yang J, Thordarson G, Talamantes F, Nandi S: Prevention of mammary carcinogenesis by short-term estrogen and progestin treatments. Breast Cancer Res. 6: 31-37, 2004.
20. Smirnoff P, Liel Y, Gnainsky J, Shany S, Schwartz B: The protective effect of estrogen againts chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol. Res. 11: 255-264, 1999.
21. Deguchi J, Miyamoto M, Okada S: Sex hormone-dependent renal cell carcinogenesis induced by ferric nitrilotriacetate in Wistar rats. Jpn. J. Cancer Res. 86: 1068-1071, 1995.
22. Lerner LJ, Jordan VC: Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture. Cancer Res. 50: 4177-4189, 1990.
23. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col FN: Meta-analysis of vascular and neoplastic events associated with tamoxifen. J. General Int. Med. 18: 937-947, 2003.
24. Lin NU, Winer EP: Advances in adjuvant endocrine therapy for postmenopausal women. J. Clin. Oncol. 26: 798-805, 2008.
25. Ingle JN: Estrogen as therapy for breast cancer. Breast Cancer Res. 4: 133-136, 2002.
26. Lø nning PE, Taylor PD, Anker G, Iddon J, Wie L, Jø rgensen LM, Mella O, Howell A: High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res. Treat. 67: 111-116, 2001.
27. Lø nning PE: Additive endocrine therapy for advanced breast cancer back to the future. Acta Oncol. 48: 1092-1101, 2009.
28. Jordan VC, Lewis-Wambi JS, Patel RR, Kim H, Ariazi EA: New hypotheses and opportunities in endocrine therapy: amplification of estrogen-induced apoptosis. Breast 18: S10-S17, 2009.
29. Maximov PY, Lewis-Wambi JS, Jordan VC, Knudson AG: The paradox of oestradiolinduced breast cancer cell growth and apoptosis. Current Signal Transduct. Ther. 4: 88-102, 2009.
30. Driggers PH, Segars JH: Estrogen action and cytoplasmic signaling pathways. Part II: The role of growth factors and phosphorylation in estrogen signaling. Trends Endocrin. Metab. 13: 422-427, 2002.
31. Segars J, Driggers P: Estrogen action and cytoplasmic signaling cascades. Part I: Membrane-associated signaling complexes. Trends Endocrin. Metab. 13: 349-354, 2002.
32. Bjö rnströ m L, Sjö berg M: Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 19: 833-842, 2005.
33. Barros RPA, Machado UF, Gustafsson JA: Estrogen receptors: new players in diabetes mellitus. Trends Molecular Med. 9: 425-431, 2006.
34. Jensen EV, Jacobson HI: Basic guides to the mechanism of estrogen action. Recent Prog. Horm. Res. 18: 387-414, 1962.
35. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 93: 5925-5930, 1996.
36. Enmark E, Pelto-Huikko M, Grandien K, Lagercrantz S, Lagercrantz J, Fried G, Nordenskjold M, Gustafsson JA: Human estrogen receptor beta-gene structure, chromosomal localization and expression pattern. J. Clin. Endocrinol. Metab. 82: 4258-4265, 1997.
37. Nilsson S, Makela S, Treuter E, Tujague J, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA: Mechanisms of estrogen action. Physiol. Rev. 81: 1535-1565, 2001.
38. Hall JM, McDonnell DP: The estrogen receptor β-isoform (ERβ ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinol. 140: 5566-5578, 1999.
39. Razandi M, Pedram A, Greene GL, Levin ER: Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERα and ERβ expressed in Chinese hamster ovary cells. Mol. Endocrinol. 13: 307-319, 1999.
40. Katzenellenbogen BS: Estrogen receptors: bioactivities and interactions with cell signaling pathways. Biol. Reprod. 54: 287-293, 1996.
41. Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA: Reflections on the discovery and significance of estrogen receptor β . Endocr. Rev. 26: 465-478, 2005.
42. Dieudonne MN, Leneveu MC, Giudicelli Y, Pecquery R: Evidence for functional estrogen receptors α and β in human adipose cells: regional specipities and regulation by estrogens. Am. J. Physiol. Cell Physiol. 286: C655-C661, 2004.
43. Krotkiewski M, Bjö rntorp P, Sjostrom L, Smith U: Impact of obesity on metabolism in men and women, importance of regional adipose tissue distribution. J. Clin. Invest. 72: 1150-1162, 1983.
44. Poehlman ET, Toth MJ, Gardner AW: Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann. Intern. Med. 123: 673-675, 1995.
45. Judd HI, Shamonki IM, Frumar AM, Lagasse LD: Origin of serum estradiol in postmenopausal women. Obstet. Gynecol. 59: 680-686, 1982.
46. Mattison R, Jensen M: The adipocyte as an endocrine cell. Curr. Opin. Endocrinol. Diab. 10: 317-321, 2003.
47. Tikhonoff V, Staessen JA: Hormonal regulation of human adipocytes at the cross roads between obesity and hypertension. J. Hypertens. 20: 839-841, 2002.
48. Huang J, Li X, Maguire CA, Hilf R, Bambara RA, Muyan M: Binding of estrogen receptor beta to estrogen response element in situ is independent of estradiol and impaired by its amino terminus. Mol. Endocrinol. 19: 2696-2712, 2005.
49. Dickson RB, Gelmann EP, Knabbe C, Jasid K, Bates S, Swain S: Mechanisms of estrogenic and antiestrogenic regulation of growth of human breast carcinoma. In: Klijn JGM (ed) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven Press, New York, pp 381-403, 1987.
50. Helguero LA, Faulds MH, Gustafsson JA, Haldosen LA: Estrogen receptors α (ERα ) and β (ERβ ) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 24: 6605-6616, 2005.
51. Patrone C, Pollio G, Vegeto E, Enmark E, de Curtis I, Gustafsson JA, Maggi A: Estradiol induces differential neuronal phenotypes by activating estrogen receptor α or β . Endocrinol. 141: 1839-1845, 2000.
52. Krege JK, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O: Generation and reproductive phenotypes of mice lacking estrogen receptor β . Proc. Natl. Acad. Sci. USA 95: 15677-15682, 1998.
53. Shim GJ, Kis LL, Warner M, Gustafsson JA: Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor α gene. Proc. Natl. Acad. Sci. USA 101: 1720-1724, 2004.
54. Shim GJ, Warner M, Kim HJ, Andersson S, Liu L, Ekman J, Imamov O, Jones ME, Simpson ER, Gustafsson JA: Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome. Proc. Natl. Acad. Sci. USA 101: 12628-12633, 2004.
55. Maruyama S, Fujimoto N, Asano K, Ito A: Suppression by estrogen receptor β of AP-1 mediated transactivation through estrogen receptor α . J. Steroid Biochem. Mol. Biol. 78: 177-184, 2001.
56. Lindberg MK, Moverare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson JA, Ohlsson C: Estrogen receptor (ER)-β reduces ERα-regulated gene transcription, supporting a 'ying yang' relationship between ERα and ERβ in mice. Mol. Endocrinol. 17: 203-208, 2003.
57. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA, Safe S: Ligand-, cell-, and estrogen J. Biol. Chem. 275: 5379-5387, 2000.
58. Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, Gustafsson JA: Update on estrogen FEBS Letters 546: 17-24, 2003.
59. Shyamala G, Ferenczy A: The nonresponsiveness of lactating mammary gland Endocrinol. 110: 1249-1256, 1982.
60. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM, Webb P: Estrogen receptor pathways to AP-1. J. Steroid Biochem. and Mol. Biol. 74: 311-317, 2000.
61. Leung KC, Johannson G, Leong GM, Ho KKY: Estrogen regulation of growth hormone action. Endocrine Rev. 25: 693-721, 2004.
62. Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC: Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res. 63: 2434-2439, 2003.
63. Shaaban AM, O'Neill PA, Davies MP, Sibson R, West CR, Smith PH, Foster CS: Declining estrogen Am. J. Surg. Pathol. 27: 1502-1512, 2003.
64. Park BW, Kim KS, Heo MK, Ko SS, Hong SW, Yang WI, Kim JH, Kim GE, Lee KS: Expression of estrogen Breast Cancer Res. Treat. 80: 79-85, 2003.
65. Martineti V, Picariello L, Tognarini I, Carbonell Sala S, Gozzini A, Azzari C, Mavilia C, Tanini A, Falchetti A, Fiorelli G, Tonelli F, Brandi ML: ERbeta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocrine-Related Cancer 12: 455-469, 2005.
66. Pravettoni A, Mornati O, Martini PG, Marino M, Colciago A, Celotti F, Motta M, Negri-Cesi P: Estrogen receptor beta (ERbeta) and inhibition Mol. Cell Endocrinol. 263: 46-54, 2007.
67. Losel R, Wehling M: Nongenomic actions of steroid hormones. Nat. Rev. Mol. Cell Biol. 4: 46-56, 2003.
68. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T: Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-l enhancer. J. Biol. Chem. 269: 16433-16442, 1994.
69. Kahlert S, Neudling S, van Eickels M, Vetter H, Meyer R, Groche C: Estrogen receptor α rapidly activates the IGF-1 receptor pathway. J. Biol. Chem. 275: 18447-18453, 2000.
70. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P: Activation of the estrogen receptor though phosphorylation by mitogen-activated protein kinase. Science 270: 1491-1494, 1995.
71. Hewitt SC, Collins J, Grissom S, Deroo B, Korach KS: Global uterine genomics Mol. Endocrinol. 19: 657-668, 2005.
72. Ankrapp DP, Bennett JM, Haslam SZ: Role of epidermal growth J. Cell Physiol. 174: 251-260, 1998.
73. Nelson KG, Takahashi T, Bossert NL, Walmer DK, McLachlan JA: Epidermal growth Proceed. Natl. Acad. Sci. USA 88: 21-25, 1991.
74. Curtis SW, Washburn T, Sewall C, DiAugustine R, Lindzey J, Couse JF, Korach KS: Physiological coupling of growth factor and steroid receptor signaling pathway: estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proceed. Natl. Acad. Sci. USA 93: 12626-12630, 1996.
75. Smith CL: Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol. Reprod. 58: 627-632, 1998.
76. Henderson BE, Ross R, Bernstein L: Estrogens as a cause of human cancer. Cancer Res. 48: 246-253, 1988.
77. Pietras RJ, Marquez-Garban DC: Membrane-associated estrogen receptor signaling pathways in human cancers. Clin. Cancer Res. 13: 4672-4676, 2007.
78. Key TJ, Applyby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE Jr, Falk RT, Miller R, Schatzkin A, Allen DS, Fentiman IS, Key TJ,Wang DY, Dowsett M, Thomas HV, Hankinson SE, Toniolo P, Akhmedkhanov A, Koenig K, Shore RE, Zeleniuch-Jacquotte A, Berrino F, Muti P, Micheli A, Krogh V, Sieri S, Pala V, Venturelli E, Secreto G, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Kuller LH, Cummings SR, Helzlsouer KJ, Alberg AJ, Bush TL, Comstock GW, Gordon GB, Miller SR, Longcope C, Endogenous Hormones Breast Cancer Collaborative Group: Body mass index, serum sex hormones and breast cancer risk in postmenopausal women. J. Natl. Cancer Inst. 95: 1218-1226, 2003.
79. Marquez DC, Pietras RJ: Membrane-associated binding sites for estrogen contribute to growth regulation in human breast cancer cells. Oncogene 20: 5420-5430, 2001.
80. Pietras RJ, Arboleda J, Wongvipat N, Ramos L, Parker MG, Sliwkowski MX, Slamon DJ: HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone independent growths in human breast cancer cells. Oncogene 10: 2435-2446, 1995.
81. Alvaro D, Barbaro B, Franchitto A, Onori P, Glaser SS, Alpini G, Francis H, Marucci L, Sterpetti P, Ginanni-Corradini S, Onetti MA, Dostal DE, De Santis A, Attili AF, Benedetti A, Gaudio E: Estrogens and insulin-like growth factor I modulate neoplastic cell growth in human cholangiocarcinoma. Am. J. Path. 169: 877-888, 2006.
82. Pietras RJ, Marquez D, Chen HW, Tsai E, Weinberg O, Fishbein M: Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cells. Steroids 70: 372-381, 2005.
83. Lundholt BK, Briand P, Lykkesfeldt AE: Growth inhibition Breast Cancer Res. Treat. 67: 199-214, 2001.
84. Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ: Estrogen receptor signaling pathways in human non-small cell lung cancer. Steroids 72: 135-143, 2007.
85. Skov BG, Fischer BM, Pappot H: Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival. Lung Cancer 59: 88-94, 2008.
86. Wu CT, Chang YL, Shih JY, Lee YC: The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J. Thorac Cardiovasc. Surg. 130: 979-986, 2005.
87. Kaway H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Minamiya Y, Ogawa J: Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. Clin. Cancer Res. 11: 5084-5089, 2005.
88. Hirashi Y, Wada T, Nakatani K, Negoro K, Fujita Sh: Immunohistochemical expression of EGFR and p-EGFR in oral squamous cell carcinomas. Pathol. Oncol. Res. 12: 87-91, 2006.
89. Lukits J, Remenar E, Raso E, Ladá nyi A, Kasler M, Timar J: Molecular identification, expression and prognostic role of estrogen-and progesterone receptors in head and neck cancer. Int. J. Oncol. 30: 155-160, 2007.
90. Egloff AM, Rothstein ME, Seethala R, Siegfriend JM, Grandis JR, Stabile LP: Crosstalk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin. Cancer Res. 15: 6529-6540, 2009.
91. Massarweh S, Schiff R: Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor crosstalk. Endocrin-Related Cancer Suppl. 13, 1: S15-24, 2006.
92. Stoner M, Wang F, Wormke M, Nguyen T, Samudio I, Vyhlidal C, Marme D, Finkenzeller G, Safe S: Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins. J. Biol. Chem. 275: 22769-22779, 2000.
93. Saceda M, Lippman ME, Chambon P, Lindsey RL, Ponglikitmongkol M, Puente M, Martin MB: Regulation of the estrogen receptor in MCF-7 cells by estradiol. Mol. Endocrinol. 2: 1157-1162, 1988.
94. Schreihofer DA, Stoler MH, Shupnik MA: Differential expression and regulation of estrogen receptors (ERs) in rat pituitary and cell lines: estrogen decreases ER-(alpha)-protein and estrogen responsiveness. Endocrinol. 141: 2174-2184, 2000.
95. Shupnik MA, Gordon MS, Chin WW: Tissue-specific regulation of rat estrogen receptor mRNAs. Mol. Endocrinol. 3: 660-665, 1989.
96. Suba Z: Estrogen deficiency as cancer risk factor. Chapter 5. pp. 85-105. in: Estrogen versus Cancer. Nova Science Publishers Inc, New York 2009.
97. Liehr JG: Is estradiol a genotoxic and mutagenic carcinogen? Endocrine Rev. 21: 40-54, 2000.
98. Santen RJ, Martel J, Hoagland M, Naftolin F, Roa L, Harada N, Hafer L, Zaino R, Santner SJ: Stromal spindle cells contain aromatase in human breast-tumors. J. Clin. Endocrin. Metab. 79: 627-632, 1994.
99. Suzuki T, Miki Y, Akahira JI, Moriya T, Ohuchi N, Sasano H: Review: Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations. Endocrine J. 55: 455-463, 2008.
100. Sasano H, Miki Y, Nagasaki S, Suzuki T: In situ estrogen production and its regulation in human breast carcinoma: From endocrinology to intracrinology. Pathology International 59: 777-789, 2009.
101. Hayes DF: Tamoxifen: Dr. Jekyll and Mr. Hyde? J. Natl. Cancer Inst. 96: 895-897, 2004.
102. Jiang J, Sarwar N, Peston D, Kulinskaya E, Shousha S. Coombes RC. Ali S.: Phosporylation of estrogen receptor-alpha at Ser167 is indicative of longer disease-free and overall survival in breast cancer patients. Clin. Cancer Res. 13: 5769-5776, 2007.
103. Osborne CK: Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339: 1609-1618, 1998.
104. Early Breast Cancer Trialist's Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351: 1451-1467, 1998.
105. McGuire WL: Estrogen receptors in human breast cancer. J. Clin. Invest. 52: 73-77, 1973.
106. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR: Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19: 1865-1878, 2001.
107. Gustaffson JA: Therapeutic potential of selective estrogen receptor modulators. Curr. Opin. Chem. Biol. 2: 508-511, 1998.
108. MacGregor JI, Jordan VC: Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 50: 151-196, 1998.
109. McDonald CC, Alexander FE, Whyte BW, Forrest AP, Stewart HJ: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. The Scottish Cancer Trials Breast Group BMJ 311: 977-980, 1995.
110. Stoica A, Saceda M, Doraiswamy VL, Coleman C, Martin MB: Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. J. Endocrinol. 165: 371-378, 2000.
111. Parvez S, Tabassum H, Banerjee BD, Raisuddin S: Taurine prevents tamoxifen induced mitochondrial oxidative damage in mice. Basic Clin. Pharmacol. Toxicol. 102: 382-387, 2008.
112. Ellis MJ, Gao F, Dehdashti F, Jeffe DB, Marcom PK, Carey LA, Dickler MN, Silverman P, Fleming GF, Kommareddy A, Jamalabadi-Majidi S, Crowder R, Siegel BA: Lower-dose versus high dose oral estradiol therapy of hormone receptor-positive,aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study. JAMA 302: 774-780, 2009.